Abstract
The study was designed to assess clinical efficiency and safety of nebivolol in patients with cardiovascular problems and chronic obstructive pulmonary disease. It included 50 patients of whom 25 were given daily 5 and 25 mg of nebivolol and 80-100 mg of verapamil. Nebivolol was shown to significantly reduce arterial pressure, heart rate, and the number of ventricular extrasystoles. The drug was well tolerated by the patients and had no adverse effect on bronchial patiency.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Adrenergic beta-1 Receptor Antagonists / therapeutic use
-
Adult
-
Aged
-
Benzopyrans / therapeutic use*
-
Coronary Disease / complications
-
Coronary Disease / diagnosis
-
Coronary Disease / drug therapy*
-
Disease Progression
-
Echocardiography
-
Electrocardiography
-
Ethanolamines / therapeutic use*
-
Follow-Up Studies
-
Humans
-
Middle Aged
-
Nebivolol
-
Nitric Oxide / metabolism
-
Pulmonary Disease, Chronic Obstructive / complications
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Pulmonary Disease, Chronic Obstructive / metabolism
-
Respiratory Function Tests
-
Treatment Outcome
Substances
-
Adrenergic beta-1 Receptor Antagonists
-
Benzopyrans
-
Ethanolamines
-
Nebivolol
-
Nitric Oxide